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APE1 is essential in cancer cells due to its central role in the Base Excision Repair pathway of DNA 
lesions and in the transcriptional regulation of genes involved in tumor progression/chemoresistance. 
Indeed, APE1 overexpression correlates with chemoresistance in more aggressive cancers, and 
APE1 protein-protein interactions (PPIs) specifically modulate different protein functions in cancer 
cells. Although important, a detailed investigation on the nature and function of protein interactors 
regulating APE1 role in tumor progression and chemoresistance is still lacking. The present work was 
aimed at analyzing the APE1-PPI network with the goal of defining bad prognosis signatures through 
systematic bioinformatics analysis. By using a well-characterized HeLa cell model stably expressing 
a flagged APE1 form, which was subjected to extensive proteomics analyses for immunocaptured 
complexes from different subcellular compartments, we here demonstrate that APE1 is a central 
hub connecting different subnetworks largely composed of proteins belonging to cancer-associated 
communities and/or involved in RNA- and DNA-metabolism. When we performed survival analysis 
in real cancer datasets, we observed that more than 80% of these APE1-PPI network elements is 
associated with bad prognosis. Our findings, which are hypothesis generating, strongly support the 
possibility to infer APE1-interactomic signatures associated with bad prognosis of different cancers; 
they will be of general interest for the future definition of novel predictive disease biomarkers. Future 
studies will be needed to assess the function of APE1 in the protein complexes we discovered. Data are 
available via ProteomeXchange with identifier PXD013368.
Alteration of DNA repair mechanisms is an important hallmark of cancer cells, and plays a role both in the onset 
of an initial cancerous phenotype and in tumor progression. Tumor cells can develop drug resistance through 
repair mechanisms that counteract the DNA damage induced by chemotherapy or radiotherapy1,2. Thus, specific 
DNA repair inhibitors are often combined with DNA-damaging agents to improve therapy efficacy. Emerging 
evidences in tumor biology suggest that: i) protein-protein interactions (PPIs) specifically modulate both canon-
ical and non-canonical roles of DNA repair enzymes; ii) RNA processing pathways participate in DNA-Damage 
Response (DDR); iii) defects in the above-mentioned regulatory mechanisms are associated with cancer genomic 
instability3. Very recent studies clearly show that many DNA repair proteins are associated with those involved 
in RNA metabolism, proving a role of their interactome network in undertaking non-canonical functions affect-
ing gene expression in tumors. In addition, novel studies have shown that interaction of DDR components and 
miRNA biogenesis process is linked to cancer development2. In the context of these emerging lines, we already 
demonstrated the crucial role that enzymes belonging to the base excision DNA repair (BER) pathway play4. In 
particular, we showed that the essential BER enzyme apurinic/apyrimidinic endonuclease 1 (APE1), which is 
encoded by the APEX1 gene, contributes to the regulation of oxidative stress responses and to the expression 
of chemoresistance genes via unsuspected functions in RNA metabolism4–8. The involvement of this protein in 
RNA processing events9–11, including miRNA expression, was recently unraveled by our group using a limited 
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unbiased functional proteomic approach4. However, the reduced characterization of APE1 interaction with pro-
teins involved in miRNA processing, e.g. NPM1, hnRNPU, PRP19, SFPQ and p5312, strongly limited our com-
plete understanding of this phenomenon and of its functional relevance in cancer biology, thus hampering a 
further translation of these findings into therapy.
It is well known that the different functions of APE1 may depend on its interacting partners13,14; for example, 
an alteration of its interaction networks has been reported to play a significant role in BER impairment. A recent 
hypothesis also suggests that APE1 functional dysregulation may impact on the RNome expression and, thus, 
on the expression of target genes playing a relevant role in the pathology onset4. Since several cancer-associated 
APE1 variants present mutations in the endonuclease domain, exhibiting only mild nuclease defects in vitro15–17, 
we hypothesize that APE1 non-canonical functions associated with its overexpression and/or an altered expres-
sion of its protein interacting partners should be related to cancer promotion. A proof of concept for the rele-
vance of APE1 PPIs in cancer biology is represented by the paradigmatic example of the APE1-nucleophosmin 
1 (NPM1) interaction, as ascertained by us18. NPM1 is a multifunctional protein that controls cell growth and 
genome stability through a mechanism either involving nucleolar-cytoplasmic shuttling or a fine modulation of 
the whole BER pathway11,19. Recently, an important role for NPM1 in miRNA biology, associated with cancer 
development, was outlined20–22. Abnormal cytoplasmic APE1 and NPM1 levels were associated with the onco-
genic progression and chemoresistance of HGSC (high-grade serous ovarian adenocarcinoma), a prediction of 
a poor prognosis therein23,24, and a dysregulation of the BER and miR-221/222 processing pathways in AML 
cells18,25. The efficacy of novel APE1/NPM1 interaction inhibitors, which sensitize cancer cells to chemotherapy 
agents, supports the translational importance of these findings26. These results further support the hypothesis that 
an alteration of other APE1 PPIs may be causally involved in cancer development and chemoresistance.
Prompted by these observations, the present work was aimed at: i) implementing the already known 
APE1-PPI network using a more efficient functional proteomics approach, and ii) defining the association of the 
APE1-PPI network with the modulation of tumor progression and chemoresistance through a systematic bioin-
formatics analysis of the Cancer Genome Atlas (TCGA) datasets. To this purpose, we used HeLa cells as a general 
and well-characterized cancer cell model to generate novel disease hypotheses and molecular diagrams. Having 
a well-characterized cell model is essential when using unbiased strategies, such as genomics and proteomics, 
in order to easily interpret data and generate novel assumptions. In this context, few years ago, we developed a 
specific HeLa cell line stably expressing a flagged tagged APE1 form for selective and efficient protein complex 
immunocapture4,17,26,27. This cell line, and its corresponding products, were characterized in both cancer and gen-
otoxic damage response contexts by means of different holistic approaches, including genomics, transcriptomics 
and proteomics4,12. In this study, we wanted to improve our previous interactomic analyses by taking advantage of 
more sensitive mass spectrometry technologies, which were here applied to the analysis of extracts from different 
subcellular compartments. Resulting data were analysed by bioinformatics in a dedicated translational perspec-
tive. Our findings support the possibility to infer APE1 interactomic signatures associated with bad prognosis 
of different cancers and will be of general interest for the definition of novel predictive biomarker signatures of 
cancers.
Results
Proteomic characterization of the APE1-PPI network. With this work, we wanted to study the rele-
vance of APE1-PPIs in cancer using an unbiased functional proteomic approach in order to expand the number 
of known APE1 PPIs, as derived from studies from this and other groups4,12. To this purpose, we used HeLa cells 
stably expressing the APE1 FLAG-tagged protein12 (WT), which were here managed to optimize the isolation 
of APE1-PPI complexes through co-immunoprecipitation experiments (Figs. 1 and 2A). Differently from our 
previous investigations12, APE1-interacting protein complexes were isolated from either the whole cell lysate, or 
nuclear- and cytoplasmic-enriched subcellular fractions. Then, resulting protein mixtures were resolved by SDS-
PAGE, and corresponding gel lanes were cut into parallel gel portions that were further subjected to proteomic 
analysis. As control experiments, we applied the same proteomic procedure to a cell clone stably transfected 
with the empty scramble vector (SCR) (Figs. 1 and 2A). As additional negative control experiments, nuclear 
and cytoplasmic cell extracts from HeLa cells expressing APE1 FLAG-tagged were co-immunoprecipitated with 
a resin lacking the anti-FLAG antibody to exclude any additional background (Fig. 2A, res). Western blotting 
analysis showed an APE1 enrichment in co-immunoprecipitated material from nuclear, cytoplasmic and total 
cell extracts of a HeLa cell clone stably expressing the flagged protein (Fig. 2A). In order to check for the quality 
of the immunoprecipitated materials, nucleophosmin 1 (NPM1) was used as a known APE1 interactor prior to 
further proteomic analysis12,18,19,28. By using this approach, a number of proteins were identified in APE1-FLAG 
co-immunoprecipitates from the above-mentioned whole-cell lysate and corresponding subcellular fractions 
(Supplementary Table S1 and Table S2). After careful filtration for false positives identified in the corresponding 
control (SCR and res) samples, 62, 31 and 394 proteins were identified as potential APE1 interactors in the whole-
cell lysate, nuclear fraction and cytoplasmic fractions, respectively, which accounted for 455 non-redundant 
proteins. A poor overlapping of components from different extracts was observed, qualitatively confirming the 
preparation specificity (Fig. 2B). Various molecules (i.e. FEN1, hnRNPK, NPM1, PABPC1, SFPQ and XRCC1) 
were already described as APE1-interacting partners in other studies from this4,12 and other groups24,29,30, con-
firming the good quality of our analysis. The following proximity ligation assays were then successfully carried 
out to validate the identified APE1-interacting proteins within cells: i) SFPQ (splicing factor, proline- and glu-
tamine-rich), DHX9 (DEAH-box helicase 9) and hnRNPK (heterogeneous nuclear ribonucleoprotein K) in HeLa 
cells (Fig. 2C and Supplementary Figs. S1 and S2); ii) hnRNPA2/B1 in the JHH-6 hepatocellular carcinoma cell 
line31 (Supplementary Fig. S1B); iii) SFPQ in the A549 lung cancer cell line (Supplementary Fig. S1C)32. The 
above-mentioned APE1-binding partners list was then added with additional proteins (n = 80) deriving from 
previous APE1-focused interactomic investigations4 to yield a final list of APE1-PPI elements (n = 535), which 
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were associated with 531 non-redundant genes. The large size of this inventory (containing direct as well as indi-
rect protein-binding partners) was rationalized based on the multiple biological functions/activities in which 
APE1 has been associated (redox control, transcriptional activity, DNA and RNA metabolism), and its localiza-
tion in various subcellular districts. This condition is similar to the one recently reported for two APE1 protein 
interactors, namely XRCC6 and XRCC5, which have been similarly demonstrated to bind both to RNA/DNA as 
well as to about 300 proteins33. Other examples of proteins having hundreds of interactors (as deduced by a single 
immunocapture experiment) are already present in the scientific literature34–37. On the other hand, this final list, 
of direct or indirect APE1-binding partners, contained about 100 proteins whose capability to interact (directly 
or indirectly) with APE1 was already ascertained by different experimental approaches (Supplementary Table S3). 
The above-mentioned protein inventory was then subjected to bioinformatics analysis to establish a PPI-network 
associated with APE1 (Fig. 1); then, we linked this analysis to additional cancer/biological databases with the aim 
to provide a more complete picture of the APE1 biological roles in both cancer and cellular biology.
APE1-PPI network construction and analysis. The APE1-interacting partners from this and other 
investigations (n = 535) were used to establish the APE1-PPI network. Direct and/or indirect interactions 
between these molecules were retrieved by the InWeb_InBioMap web tool, which is a large data compendium for 
high-quality PPI networks. Afterwards, the undirected PPI network, representing the interactome of APE1, was 
constructed with 511 nodes (24 proteins were not recognized by the tool) and 3934 edges (Fig. 3A). The resulting 
network was visualized and analyzed by using the Cytoscape software and its packages38. The initial analysis of 
the network was carried out by performing functional enrichment analysis for terms belonging to the “Gene 
Ontology - Biological Process” database, using the ClueGO tool with standard parameters to identify enriched 
pathways on the basis of the network’s gene frequency in each pathway (n = 383, 75%). Based on this analysis, 109 
genes were enriched in the group of pathways called “DNA metabolic process” (7.4% genes per group), 90 genes 
Figure 1. Schematic experimental pipeline used in this study. Schematic representation of the workflow for 
ascertaining APE1-interacting proteins by proteomic experiments. Whole-cell lysates (WCE), or nuclear 
(NCE) and cytoplasmatic (CCE) extracts were prepared from the 3 × APE1 FLAG-tagged expressing cells or 
control cells transformed with an empty vector (SCR). M2 antibodies against the FLAG peptide were used 
for co-immunoprecipitation of the above cell lysates. As additional control experiment, identical cell extracts 
from HeLa cells expressing 3 x APE1 FLAG-tagged were also co-immunoprecipitated with a resin lacking the 
FLAG antibody (res). The resulting bound proteins were digested with trypsin and analyzed by nanoLC-ESI-Q-
Orbitrap-MS/MS. By comparison with proteins identified in the control co-immunoprecipitation experiments, 
we removed contaminant proteins from components identified in WCE, NCE and CCE; the resulting APE1-
interacting partners were further added of additional proteins binding to APE1 (n = 80) from previous studies4, 
and finally subjected to bioinformatics analysis.
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Figure 2. Proteomic characterization of the APE1 interactome. (A) Representative Western blotting to confirm 
APE1 pulldown in the co-immunoprecipitation experiment. Western blotting analysis was performed on total 
HeLa cell clone extracts (INPUT) and on co-immunoprecipitated material (IP) with specific antibodies for 
APE1 and FLAG. The endogenous (endo) and ectopic (ecto) form of the APE1 protein is visible. The resulting 
material was tested for the occurrence of NPM1, a known APE1 interactor. LSD1 was used to probe nuclear 
enrichment. SCR, HeLa cell clone transfected with empty vector; WT, HeLa cell clone expressing APE1-FLAG 
tagged protein; res, co-immunoprecipitated with a resin lacking the FLAG antibody; WCE, whole cell extract; 
NCE, nuclear cell extract; CCE, cytoplasmic cell extract. (B) Venn diagram showing APE1-interacting partners 
identified in whole-cell lysates (WCE), or nuclear (NCE) and cytoplasmatic (CCE) extracts. (C) Nucleoplasmic 
interaction between APE1 and three identified interactors. HeLa cells were seeded on a glass coverslip and the 
PLA reaction was carried out using anti-APE1, anti-SFPQ, anti-DHX9 and anti-hnRNPK antibodies. APE1 
localization was detected by using an anti-APE1 antibody and visualized in green. Confocal microscopy analysis 
highlighted the presence of distinct fluorescent red dots (PLA signals) indicating the occurrence of in vivo 
interaction between APE1 and its protein partners. DAPI staining was used as a reference for the nuclei. See also 
Supplementary Figs. S1 and S2 for negative controls. Bars, 8 µM.
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were enriched in the group of pathways called “mRNA metabolic process” (6.1% genes per group), 54 genes were 
enriched in the group of pathways called “DNA damage response” (3.7% genes per group) and 27 genes were 
enriched in the group of pathways called “RNA localization” (1.8% genes per group) (Fig. 3B and Supplementary 
Table S4). These results clearly confirmed the involvement of APE1 and its interacting partners in processes 
involved in RNA (with particular emphasis on mRNA), DNA and protein metabolism/stability, supporting our 
previous findings4,12.
The complex PPI-network containing 511 nodes was then studied in order to focus on its most important 
elements; this was done through a hub analysis based on global metric, betweenness centrality. In graph the-
ory, betweenness centrality is a measure of centrality in a graph based on the shortest paths; therefore, it repre-
sents the degree to which nodes stand between each other. As a result, the top 30 hub nodes were identified and 
Figure 3. Bioinformatics characterization of the APE1 interactome. (A) Global APE1 Protein-Protein 
Interaction Network. (B) Functional annotation of the global network based on Gene Ontology - Biological 
Process terms (p < 0.05). In the pie chart, the percentage of the proteins/genes enriched in the group of 
pathways is shown. (C) Top 30 hubs of the APE1-PPI network, based on global metric, betweenness centrality. 
Color shades represent the significance of the hub, with red color as the most significant and yellow color as 
the least. (D) Functional annotation of the Top 30 hubs based on Gene Ontology - Biological Process terms 
(p < 0.05). In the pie chart, the percentage of the genes enriched in the group of pathways is shown. (E) 
Transcriptional regulatory network of the APE1 interactome. Node size represents the number of putative 
binding sites identified by the LASAGNA-Search 2.0 tool in the promoters (−2500, -1nt from the TSS) of the 
APE1 interactome genes for 16 transcription factors that are modified by APE1 redox activity or use APE1 as a 
co-factor.
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extracted from the main APE1-PPI network as hub-subnetworks (Fig. 3C). This hub module was then analyzed 
with ClueGO to understand the specific roles of these genes in biological processes (Fig. 3D and Supplementary 
Table S4). The predominant enrichment was observed for: i) 12 hub genes involved in the group of pathways 
named “signal transduction in response to DNA damage” (31.6% genes per group); ii) 6 hub genes enriched in 
the group of pathways called “regulation of mRNA stability” (15.8% genes per group); iii) 3 central hub genes 
(HSPA1A, PRPF19 and PSMD4) involved in the group of pathways related to “positive regulation of RNA splic-
ing”, confirming previous interactomic results4. Globally, these results indicate the significant involvement of the 
APE1-PPI network in RNA and DNA metabolism, showing that APE1 acts as the central hub connecting differ-
ent subnetworks with diverse functions.
Role of APE1 in the transcriptional regulation of the APE1-PPI network. Among its multifunc-
tional biological roles, APE1 is also known as transcriptional and post-transcriptional regulator. On the one hand, 
APE1 can exert its nuclear redox control function on several transcription factors (TFs), modulating their activity 
and, hence, gene expression39. On the other hand, it can also act at the RNA level through its ability in binding 
to transcripts, thus affecting corresponding stability and processing4,10. Therefore, we can hypothesize that APE1 
may contribute to gene expression regulation of elements of its own PPI. In order to check whether APE1 could 
be involved in the former activity, we performed a TFBS motif discovery analysis with the LASAGNA-Search 2.0 
tool40 on the promoters of the above-mentioned 531 genes representing the APE1 interactome. This allowed to 
verify and quantify the presence of enriched putative binding sites for more than a hundred TFs (Supplementary 
Table S5). In particular, we identified putative sites for 16 TFs that are known to be stimulated by the APE1 redox 
activity or to regulate gene expression by using APE1 as a co-factor (e.g. AP1, NF-κB1, HIF1α and members 
of the STAT family) (Fig. 3E). Some of these TF binding sites (e.g. PAX5 sites) were not highly abundant in the 
obtained results but, since they are known to regulate gene expression in a tissue-specific manner, we believe that 
the HeLa cell model used in the present work could not represent the most suitable one to study their effect. We 
also compared the list of APE1-PPI partners identified in the present work with that of the RNA molecules bound 
by APE1 (n = 1015), which we previously had defined through RIP-seq experiments4,12; this analysis demon-
strated that 42 genes, that interact with APE1 at the transcript level, are also part of the APE1-PPI (p-value = 0.01, 
Supplementary Fig. S3). We finally integrated these data with the results of a microarray differential gene expres-
sion profiling analysis performed in siAPE1 HeLa cells12. Interestingly, we found that 55 genes, belonging to 
the APE1-PPI network, were differentially expressed (absolute log fold change ≥1, adj. p-value ≤ 0.05), as 
well as 45 other transcripts originating from the RIP-seq experiment, globally accounting for 95 unique genes 
(p-value = 0.0001, Supplementary Fig. S3). Altogether, these results strongly support the possibility that APE1 
may contribute to the regulation of the expression of the majority of its own PPI genes.
Correlation between APE1 and its protein-binding partners at the gene expression 
level. Correlated expression of differently associated genes is often observed being a common feature and an 
important booster of the transformation process41, even though a perfect correlation of gene expression at mRNA 
and protein levels is not always observed42. However, data described in the previous section provided interesting 
evidences suggesting that the integration of proteomic and transcriptomic data, correlated by common biological 
functions, may highlight the potential involvement of subsets of genes in neoplastic transformation.
In order to understand if a relationship between APE1 and its protein interaction partners may be observed 
also at the gene expression level, we analyzed the corresponding correlations in the Genomic Data Commons 
(GDC) RNA-Seq tumor database. In more than 11,000 tumor sample datasets, we observed that the gene expres-
sion correlation between APE1 and its PPI-network elements is higher (p-value < 1015) than that with respect to: 
(i) all the genes, (ii) random-gene datasets (PPI size) or iii) random genes vs the APE1-PPI network (Fig. 4A,B). 
By using the same dataset, gene expression data for the genes coding the 531 interactors of APE1 were obtained 
for 33 different tumor types described in TCGA (Supplementary Table S6) as well as for the associated normal 
tissues. Further analyses were performed across the top 11 TCGA cancer datasets having the highest number 
of bad prognostic genes (see below) that were up- and down-regulated (p < 0.05, absolute log fold change >1) 
(Figs. 4C, 5 and Supplementary Table S6). According to the results of the differential gene expression analysis, 
more than half of the APE1 interactors were found to be differentially expressed in many datasets (Fig. 4). The 
gene expression of APE1 across these datasets was used to calculate the Pearson correlation existing between 
APE1 and its interactors. A very high percentage of differentially expressed genes (DEGs) in those datasets was 
found to have significant (p < 0.05) correlation with APE1 gene expression (Fig. 4C). Altogether, these results 
demonstrated the existence of a very strong orchestration in the expression of APE1 and of its interacting proteins 
in the aforementioned cancer types, suggesting the existence of common pathways of transcriptional regulation 
for APE1-PPIs in cancer development.
Upstream regulators analysis. With the aim of ascertaining the role of these gene modules in more detail, 
an upstream regulators analysis was performed using the TRANSPATH tool within the geneXplain 4.11 web plat-
form. For each TCGA cancer dataset, the list of significant DEGs was analyzed, and the three molecules having 
the lowest Ranks sum were retained (Table 1) as the ones having the best probability of being the master regu-
lators of that network. These results strengthened, on the one hand, the general role of the modules in RNA and 
DNA repair mechanisms. In fact, XRCC6 (master regulator of 5 datasets) and DDB1 (master regulator of 3 data-
sets) are proteins associated with the DNA repair process43,44. YBX1, another highly represented master regulator 
(KIRC, KIRP and PAAD), is known to act as both an RNA- and a DNA-binding protein, as well as being involved 
in miRNA processing45. However, what really equated all these regulators was their role in the apoptotic, prolif-
erative and resistance pathways, as shown in Table 1. We also evaluated the correlation of the expression profiles 
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Figure 4. Differential gene expression and correlation analysis of APE1-interacting partners in the TCGA 
datasets. (A) Empirical cumulative distribution function (ECDF). Empirical cumulative distribution curves 
of the correlation of the gene expression profiles of APEX1 and APEX1-PPI network genes in the TCGA 
datasets or in the control groups. Green line: APEX1 expression versus the PPI network genes; red line: APEX1 
expression versus 100 sets with the same size of the PPI gene set composed by random genes; blue line: 100 
random genes expression versus the PPI network genes; black line: APEX1 expression versus all genes. Note 
that the black line is nearly superimposed to the red line and, for this reason, almost hidden by it. (B) Box-
plots of the same data. The average correlations for all the control groups are statistically significantly different 
(p < 0.005) with respect to the APEX1-PPI correlation. (C) Total number of differentially expressed genes 
(p < 0.05, absolute log fold change difference > 1) across the top 11 TCGA datasets having the highest number 
of up- and down-regulated genes. In the bar chart, the number of genes having significant correlation (absolute 
(PCC) >0.6, p < 0.05) with the expression of APE1 is shown in orange, while the others are shown in green.
Figure 5. Survival analysis of APE1-interacting partners in the TCGA datasets. For each cancer type, bar plots 
represent the percentages and the total number of genes having significant (p < 0.05) bad or good prognosis, 
shown in orange and green color, respectively.
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of APEX1 and of these regulators in each bad prognostic network (Fig. 6 and Supplementary Figs. S4–S11, data 
is represented according to a color code).
Afterwards, upstream regulators analysis was performed also on the global APE1-PPI network to widen our 
understanding of its functions. The resulting top 10 master regulators are provided in Supplementary Table S8. 
Interestingly, we observed that some of these master regulators (i.e. NUAK1, KDM1A, UBE2D1, RBX1 and 
UBE2M) were known to be associated with the p53 signaling pathway46–51.
Definition of a bad-prognostic APE1 signature in cancers. With the aim of evaluating the real impact 
of APE1-interacting partners in TCGA cancer datasets, survival analyses were performed using the RTCGA 
Bioconductor package. The genes that were differentially expressed in a statistically significant manner (p < 0.05, 
absolute log fold change >1) between tumor and normal tissues were analyzed; Kaplan-Meier plots were obtained 
for each gene in each dataset, allowing to define good and bad prognosis gene signatures on a per cancer basis 
(Supplementary Table S4). The distribution of the genes with respect to significant good or bad prognosis 
(p < 0.05) in those cancer datasets is represented in Fig. 5.
In order to focus our attention on the most relevant cancer types, we based our bioinformatic analysis on the 
eleven datasets having the highest number of bad prognostic genes. Among those, we were interested in par-
ticular in liver (LIHC)52–56, lung (LUAD)57–60 and pancreatic (PAAD)61–65 cancer datasets, as the essential role of 
APE1 in the tumorigenic processes of these cancer types is already well established. Notably, the LUAD dataset 
was the third having the highest number of bad prognostic genes (n = 153). We then represented these genes as 
a subnetwork of the APE1-PPI network having correlation information with the following color code: green for 
significant positive correlation (PCC >0.6), red for significant negative correlation (PCC <−0.6) and grey for 
no correlation (Fig. 6A). In the network, the top 3 master regulators were also represented with diamond-shaped 
nodes. Afterwards, we specifically studied the survival outcomes of patients with high or low expression of the 
bad prognosis signature, using the median log fold change value of the genes in the network. The Kaplan-Meier 
plot (Fig. 6B) clearly shows that high expression of the genes in the bad prognostic network was associated with 
significant (p < 0.0001) lower survival probability. The biological processes dominantly enriched in this network 
were as follows: nucleic acid metabolism, protein transporters and arrangements to form complex subunits that 
have polymerized to generate fiber-shaped structures (Fig. 6C and Supplementary Table S4).
Because of the strong interest in APE1 as a prognostic factor in liver52–56 and pancreatic cancers61–63, we 
applied the same representation also to the LIHC (Fig. 6D–F) and PAAD datasets (Fig. 6G–I) with a total number 
of 91 and 64 bad prognostic genes, respectively. The bad prognostic signatures in these networks highlighted 
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TERF2 (1) (2) (3) Telomeric repeat binding factor 2





YBX1 (1) (2) (3) Y-Box binding protein 1
LUAD PRKN (2) Parkin RBR E3 ubiquitin protein ligase HDAC2 (1) (2) (3)
Histone deacetylase 
2 XRCC6 (1) (2) (3)
X-ray repair cross-
complementing protein 6
UVM SMYD2 (1) (2) (3) SET and MYND domain containing 2 KDM1A (1) (2) (3)
Lysine demethylase 
1 A XRCC5 (1) (2)
X-ray repair cross-
complementing protein 5
LGG SETD7 (1) (2) (3)
SET domain containing 
7, histone lysine 
Methyltransferase
KDM1A (1) (2) (3) Lysine demethylase 1A CUL1 (1) (2) Cullin-1
SKCM DDB1 (1) (2) (3) Damage specific DNA binding protein 1 PTP4A3 (1) (2) (3)
Protein tyrosine 
phosphatase 4A3 XRCC6 (1) (2) (3)
X-ray repair cross-
complementing protein 6
LIHC PRKN (2) Parkin RBR E3 ubiquitin protein ligase HDAC2 (1) (2) (3)
Histone deacetylase 
2 XRCC6 (1) (2) (3)
X-ray repair cross-
complementing protein 6
KIRP YBX1 (1) (2) (3) Y-Box binding protein 1 PTP4A3 (1) (2) (3) Protein tyrosine phosphatase 4A3 TCF21 (1) (2) (3) Transcription factor 21




IDE (1) (2) Insulin-degrading enzyme




TRIM28 (1) (2) (3) Tripartite motif containing 28
PAAD YBX1 (1) (2) (3) Y-Box binding protein 1 ACTL6A (1) (2) Actin-like protein 6A HNRNPK (1) (2) (3)
Heterogeneous nuclear 
ribonucleoprotein K
Table 1. APE1-PPI bad prognostic signatures top regulators analysis. GeneXplain identification of the Top 3 
putative master regulators (ranked by ascending Ranks sum) of bad prognostic genes in the 11 selected TCGA 
cancer datasets. Numbers in brackets refer to the presence of bibliographic evidence associating upstream 
regulators with proliferation (1), apoptosis (2) and resistance (3), respectively. For TCGA abbreviations, see 
Supplementary Table S6; for all the references Supplementary Table S7.
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general, the results of survival analysis emphasized the importance of the APE1-PPI network for real clinical data. 
Specifically, 84.3% of the genes (n = 451) present in the APE1-PPI network was associated with bad prognosis in 
one or more cancer datasets.
Figure 6. The most relevant cancer-specific prognostic subnetworks in the APE1 interactome. (A,D,G) Bad 
Prognosis networks of the LUAD (A), LIHC (D) and PAAD (G) datasets formed by the protein interactors of 
APE1. Circular nodes represent the interactors of APE1, while diamond nodes represent the top 3 upstream 
regulators of the network. APE1 is symbolized with the white color as the central node. Significant negatively 
correlated nodes are symbolized with the red color (PCC < −0.6), while the nodes having significant positive 
correlation (PCC >0.6) are symbolized with the green color. Upstream regulators are symbolized with the 
purple color and the rest of the nodes are symbolized with the grey color. (B,E,H) Survival probability of 
the patients having high and low median expression of the gene signatures forming the overall networks, as 
represented by Kaplan-Meier plots. (C,F,I) Functional annotation of the Bad Prognosis networks based on Gene 
Ontology - Biological Process terms (p < 0.05). In the pie chart, the percentage of the genes enriched in the 
pathways is given next to the enriched terms.
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APE1-inhibitors sensitize cancer cells to mitochondrial toxicant Rotenone. In order to refine our 
study and to provide an additional level to the functional characterization of APE1-PPI, we finally performed 
a comparative bioinformatics analysis to define the cellular localization of DEGs, as obtained from the LIHC, 
LUAD and PAAD datasets. As shown in Fig. 7A, 24.4% of the DEGs in LIHC, 21.4% of the DEGs in LUAD and 
16.8% of the DEGs in PAAD represented APE1-PPIs that can also localize to mitochondria. Interestingly, 89.7%, 
90.4% and 62.5% of these DEGs were observed to be upregulated in the corresponding TCGA datasets. The mito-
chondrial compartments and expression trends associated with these DEGs are shown in Fig. 7B.
With the aim to support APE1 involvement in mitochondrial functionality, we performed a caspase activity 
assay upon treatment with Compound #3, an APE1 endonuclease inhibitor66, in combination with rotenone, 
a well-known mitochondrial respiratory chain inhibitor67. HeLa cells were treated with different concentra-
tions of Compound #3 in the presence/absence of rotenone (at the doses of 0.5 μM and 5 μM) for 24 h (Fig. 7C) 
(Supplementary Fig. S12). HeLa cells treated with the combination of both compounds resulted more sensitive to 
apoptosis, demonstrating the existence of a synthetic lethality relation between APE1 and mitochondrial activity, 
which may be further explored for designing novel anticancer strategies.
Discussion
The multifunctional DNA repair protein APE1 is a central enzyme in the BER pathway, and it has also been 
involved in the regulation of cellular response to genotoxic damage via direct and indirect mechanisms. In addi-
tion to the primary roles of APE1 in DNA damage repair, emerging evidences indicate that APE1 may also con-
trol RNA metabolism processes and thus gene expression4,13,68. In order to better clarify these novel functional 
aspects, we used well-established systems biology methods as optimal procedures to dissect/identify newly arising 
roles and possible mechanisms involving APE1. In this study, we focused on interactomic information obtained 
from previous studies4,12 as well as from novel experiments, which were performed using sensitive mass spec-
trometry technologies applied to the analysis of subcellular compartments. This allowed defining a final list con-
taining 535 APE1-PPI elements that were finally subjected to a deep bioinformatics investigation.
Starting from this comprehensive list of proteins, the identification of direct and/or indirect interactions 
among APE1-binding partners was deduced, and a direct/indirect PPI network representing the global inter-
actome of APE1 was constructed. This network, which was composed of 511 nodes and 3934 edges, retained 
a level of complexity that hampered the full understanding of the specific properties of each node. Therefore, a 
hub analysis was accomplished to define the top 30 nodes that were crucial for the communication of the whole 
network. Specifically, hub analysis was performed on betweenness centrality, a global metric that determines the 
involvement of each node in the information flow within the network. As a consequence, this method allowed 
the identification of the most informative proteins (hubs) for optimized therapeutic targeting in specific tumors 
(based on further bioinformatic analyses reported below). Among the most important hubs, APE1, SUMO1, 
SUMO2, TP53, ESR1, MDM2, PSMD4 and ACTB are worth mentioning (Fig. 3C). The resulting hub module was 
then analyzed with the Cytoscape plugin ClueGO to understand the role of these proteins in biological processes; 
the obtained results pointed to the involvement of these proteins mainly in DNA damage, mRNA stability and 
RNA splicing (Fig. 3D and Supplementary Table S4), indicating how these pathways were intertwined through 
the central role of APE1.
These data corroborated an emerging evidence in tumor biology; in fact, many DNA repair proteins are asso-
ciated with those involved in RNA metabolism, thus proving a substantial role of the corresponding interactome 
networks in determining their non-canonical functions, which impact on gene expression in tumor cells3. These 
considerations emphasized the importance of understanding the regulatory behavior of APE1-interacting part-
ners in various cancer datasets. To achieve this, the differential expression profiles and the gene expression cor-
relations of APE1 and its interacting partners were calculated through the analysis of 33 TCGA datasets. The top 
11 datasets with the highest number of differentially expressed genes, together with their correlation information, 
are represented as a bar chart in Fig. 4C. A very high percentage of differentially expressed genes was observed 
to have a significant prognostic potential, which was indicative for the relevance of these gene sets for related 
cancers (Fig. 5). These 11 gene sets were then subjected to survival analysis for a better understanding of their role 
according to a clinical perspective. LIHC, LUAD and PAAD networks, which were composed of bad prognostic 
genes in high percentages, confirmed previous studies on the important role of APE1 in these cancers52–55,57–65. 
Kaplan-Meier estimation was used to calculate survival probability associated with these genes; the ones having 
significantly lower survival prognosis (p < 0.05) were used to create cancer-specific PPI subnetworks (Fig. 6 and 
Supplementary Figs. S4–S11). These cancer-specific bad prognostic network signatures unveiled potential protein 
interactor targets to be further probed by novel therapeutic approaches.
In addition, the top 11 datasets were used to perform the upstream regulators analysis for wider understand-
ing of the regulatory events acting on the gene sets and the top 3 master regulator genes, as well as their involve-
ment in the apoptotic, proliferative and resistance pathways, were characterized. Out of 11 datasets, XRCC6 was 
found to be one of the top 3 master regulators in 5 datasets (i.e. HNSC, LUAD, LIHC, SKCM and BRCA), together 
with its interacting partner XRCC5, which was the master regulator of 2 datasets (UVM and BLCA). XRCC6 and 
XRCC5 are coding the proteins Ku70 and Ku80, which form a molecular heterodimer involved in the initial step 
of the non-homologous end joining (NHEJ) pathway. Ring-shaped Ku complex directs DNA-dependent protein 
kinase catalytic subunit (DNA PKcs coded by PRKDC/XRCC7) to the DNA ends, and triggers its kinase activity 
for DNA repair69. Interestingly, PRKDC was found among APE1 interactors as a component having a high corre-
lation and bad survival prognosis in various datasets. It was previously reported that genetic variants of PRKDC 
play an important role in splicing regulation, causing mRNA instability70. PRKDC and XRCC6 play an important 
role in the suppression of chromosomal rearrangements and in the maintenance of genome integrity, along with 
a significant function in the recognition and repair of double strand breaks70. Therefore, their roles were studied 
in various cancers, such as breast71,72, glioma73, renal74, hepatocellular75,76, digestive77, bladder78 and lung70 cancer. 
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Figure 7. Differentially expressed APE1-PPIs in LIHC, LUAD and PAAD datasets point to the relevance 
of mitochondrial pathways impairment in cancer. (A) Differentially expressed APE1 interactors with 
mitochondrial localization. The colour codes are as follows: bright green colour for up-regulated DEGs that 
can localize to mitochondria, bright orange colour for down-regulated DEGs that can localize to mitochondria, 
light green and light orange colours for up- and down- regulated DEGs that do not localize to mitochondria, 
respectively. (B) Localization of DEGs in the mitochondrial compartments. Specific mitochondrial sub-
compartmentalization of DEGs is shown. For each location, the global expression trend and dataset information 
is given with arrow and colour codes. Upside arrow represents up-regulation, while downside arrow represents 
down-regulation. The colour of the arrows represents the datasets as follows: grey colour for LIHC, purple 
colour for LUAD and blue colour for PAAD. (C) Inhibition of APE1 endonuclease activity in combination with 
treatment with rotenone sensitizes HeLa cells to apoptosis. Cells were treated with Compound #3 in the absence 
or presence of rotenone (0.5 and 5 µM), for 24 h. The Apo-ONE assay was used to quantify relative levels of 
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On the other hand, Ku complex is known to interact with RECQL4 and to form a macromolecular assembly 
promoting NHEJ. A well-known RECQL4-binding partner, namely DDB179, was found to be one of the top 3 
master regulators of 3 datasets (SKCM, BLCA and BRCA). DDB1 has been reported to be involved in the damage 
recognition step of the BER pathway80, and to be correlated with a high risk when down-regulated in head and 
neck squamous cell carcinoma81. The oncogenic transcriptional factor of RECQL4, namely YB1 (coded by YBX1), 
was here recognized as an interacting partner of APE1 and a master regulator observed in KIRC, KIRP and PAAD 
datasets. YB1 was found to be overexpressed in various cancer types and frequently associated with poor outcome 
and chemotherapy resistance82,83. It has also been reported to act as both an RNA- and DNA-binding protein, 
and as a component involved in miRNA processing45,84. These findings underline the important involvement of 
APE1-centered prognostic networks mainly in DNA repair, with the association of RNA metabolism in various 
cancer types.
Among the remaining top regulators identified in this study, we also found some important genes that might 
give some clues about the general involvement of the APE1 interactome in the p53 signaling pathway. In par-
ticular, some of the top 10 master regulators that were associated with the p53 signaling pathway (i.e. NUAK1, 
KDM1A, UBE2D1, RBX1 and UBE2M) deserved particular attention. For example, NUAK1 is known to be 
involved in DNA damage response by phosphorylating p53 and participating in the transcriptional regulation 
of the CDKN1A promoter46. Since NUAK1 is phosphorylated by AKT47, it has been hypothesized that this 
protein could be involved in acting between ATR and CDKN1A in response to low doses of UV irradiation48. 
Analogously, the master regulator KDM1A (LSD1) was hypothesized to be a potential therapeutic target for the 
estrogen-regulated type I endometrial cancer because of its crucial role in the LSD1/cyclin D1/PI3K/AKT feed-
back loop49. On the other hand, Zhou and colleagues recently reported that UBE2D1 facilitated the growth of 
hepatocellular carcinoma in vitro and in vivo by decreasing the p53 protein level in an ubiquitin-dependent man-
ner50. Interestingly, the master regulators UBE2M and RBX1 were also reported to have up-regulation together 
with other neddylation enzymes to highlight overexpression of the neddylation pathway in HCC51. In conclusion, 
our analysis of the global network indicated the relation of APE1 and its interactors with DNA repair mech-
anisms, and the possible involvement of the p53 signaling pathway, as confirmed by the identification of p53 
binding sites among the significantly enriched TFBS located in the promoters of APE1-PPI genes. However, 
what associated the highest number of top regulators was their role in the apoptotic, proliferative and resistance 
pathways.
In order to further characterize the LIHC, LUAD and PAAD TCGA datasets, the corresponding DEGs 
were examined also considering their subcellular locations. As a result, 24.4% of DEGs in LIHC, 21.4% of 
DEGs in LUAD and 16.8% of DEGs in PAAD datasets pointed to the involvement of APE1-PPIs in mitochon-
dria functionality (Fig. 7). For example, the bad prognostic gene VDAC1 (voltage dependent anion channel 
1), which is a multifunctional mitochondrial protein and an important regulator of cancer cell fate through 
its metabolic and energetic functions85,86, was commonly up-regulated in all 3 datasets. Similarly, many other 
mitochondria-resident APE1-PPIs were found to be commonly up-regulated in the analyzed datasets. Among 
these, it is worth mentioning: (i) SHMT2 (serine hydroxymethyltransferase), that mainly localizes to the matrix, 
nucleoid and inner membranes, and is known to be targeted by c-myc for cell survival, with various studies 
confirming its bad prognostic power in different cancer types87–91; (ii) pro-apoptotic protein SLC25A6 (mito-
chondrial ADP/ATP carrier-3, AAC3)92,93; (iii) ROS regulating respiratory complex III protein UQCRC2 
(ubiquinol-cytochrome c reductase complex core protein 2)94; (iv) respiratory complex II protein SDHB (suc-
cinate dehydrogenase B)95; v) fatty acid β- oxidation proteins ETFA (electron transfer flavoprotein subunit 
alpha)96,97 and ACAA2 (acetyl-CoA acyltransferase 2)98; vi) bad prognostic multifunctional LGALS3 (galectin-3) 
protein99; (vii) autoimmunity protein HARS (histidyl-tRNA synthetase)100; (viii) oxidative damage control pro-
tein IDH1 (isocitrate dehydrogenase 1)101. Additional matrix proteins were found being up-regulated in LIHC 
and LUAD, while down-regulated in PAAD; they included fatty acid β-oxidation proteins ECHS1 (enoyl coen-
zyme A hydratase short chain 1)102 and ETFB (electron transfer flavoprotein subunit beta)103, multifunctional 
protein 17β-HSD10 (17β-hydroxysteroid dehydrogenase type 10, encoded by HSD17B10)104 and mitochondrial 
protein processor PMPCA (mitochondrial-processing peptidase subunit alpha)105. The relevance of APE1 func-
tion within mitochondria in tumor cells has recently been highlighted by our106 and other publications107, empha-
sizing a pivotal role for APE1 in mitochondrial-mediated signalling in cancer cells, thus opening new perspectives 
in cancer therapy.
Testing on a limited set of APE1-interacting partners, we previously observed that the APE1-interactome is 
dynamically regulated during genotoxic stress conditions4 with an enrichment of proteins involved in BER, while 
losing interaction with typical proteins involved in RNA metabolism. It would be interesting to extend this study 
to the whole APE1-PPI network described here. On the same track, it would be interesting to specifically evalu-
ate the contribution of DNA and RNA molecules in modulating the APE1-PPI network dynamics. Information 
on the latter aspects may be obtained by characterizing the APE1-interactome before and upon the enzymatic 
removal of RNA and DNA. In conclusion and for the sake of clarity, we must state that this work is hypothesis 
generating and future studies will be needed to assess the function of APE1 in the protein complexes we discov-
ered. Our current work is actually focused along these lines.
apoptosis. The activities of caspases 3/7 were examined using a fluorescence-based assay. Data were normalized 
on untreated cells and represent the means ± SD of three independent experiments. Asterisks represent a 
significant difference with respect to cells treated with Compound #3 alone. Data were evaluated statistically by 
two-tails Student t-test.
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Materials and Methods
Cell line and materials. Inducible HeLa cell clones silenced for endogenous APE1 and reconstituted with 
the ectopic FLAG-tagged APE1 form were used11. HeLa cell clones were grown in Dulbecco’s modified Eagle’s 
medium (Invitrogen, Monza, Italy) supplemented with 10% v/v fetal bovine serum (Euroclone, Milan, Italy), 
100 U/ml penicillin, 10 μg/ml streptomycin sulphate, 3 μg/ml blasticidin, 100 μg/ml zeocine, 400 μg/ml geneticin 
(Invitrogen), and cultured in a humidified incubator containing a 5% CO2 atmosphere, at 37 °C. For inducible 
APE1-shRNA experiments, doxycycline (1 μg/ml) (Sigma-Aldrich, St. Louis, MO) was added to the cell culture 
medium and cells were grown for 10 days. JHH-6 cells (undifferentiated hepatocellular carcinoma)31 were cul-
tured in William’s medium E (Sigma-Aldrich), while A549 (adenocarcinomic human alveolar basal epithelial 
cells)32 cells were cultured in RPM1 (Euroclone); both cell cultures were supplemented with 10% v/v fetal bovine 
serum, 100 U/ml penicillin, 10 μg/ml streptomycin sulphate. All cell lines were tested for mycoplasma contami-
nation (N-GARDE Mycoplamsa PCR Reagent, Euroclone).
Preparation of cell extracts and co-immunoprecipitation. Immunoprecipitation studies were carried 
out with whole cell extracts, and nuclear or cytoplasmatic subfractions of HeLa cell clones as already reported11,108 
(see Supplementary Material and Methods for details).
Immunofluorescence confocal and Proximity Ligation analyses. Immunofluorescence procedures 
and Proximity Ligation Assay (PLA) (Duolink, Sigma-Aldrich) were carried out as described earlier4. PLA was 
performed following the manufacturer’s instructions. Cells were visualized through a Leica TCS SP8 confocal 
system (Leica Microsystems GmbH, Germany). See Supplementary Material and Methods for the list of the anti-
bodies used.
Antibodies used and Western blotting analysis. For Western blotting analyses, cell lysates were 
resolved on 12% T SDS-PAGE, transferred onto nitrocellulose membranes (AmershamTM ProtranTM, GE 
Healthcare) and probed with the indicated antibodies (see Supplementary Material). The corresponding sec-
ondary antibodies labeled with IR-Dye (anti-rabbit IgG IRDye 680 and anti-mouse IgG IRDye 800) were used. 
Detection was performed with the Odyssey CLx Infrared imaging system (LI-COR GmbH, Germany). Protein 
bands were quantified using Odyssey software (Image Studio 5.0). Original uncropped images of western blots 
used in this study can be found in Supplementary Fig. S13.
Proteomic analysis. Immunopurified proteins from whole, nuclear and cytoplasmic cell extracts of HeLa 
cell clones expressing ectopic APE1 FLAG-tagged protein or stably transfected with the empty vector12 (SCR) 
were analyzed in parallel by 12% T SDS-PAGE. As additional control experiment, identical cell extracts from 
HeLa cells expressing APE1 FLAG-tagged were also co-immunoprecipitated with a resin lacking the FLAG anti-
body (res). After staining with colloidal Coomassie blue, whole gel lanes from all samples were cut into 12 slices, 
minced and washed with water. Corresponding proteins were separately in-gel reduced, S-alkylated with iodo-
acetamide and digested with trypsin, as previously reported109 and subjected to mass spectrometry analysis as 
detailed in Supplementary Material and Methods. A careful filtration for false positives ascertained in control 
samples (SCR and res) from whole, nuclear or cytoplasmic cell extracts allowed identifying APE1-binding pro-
teins in APE1-FLAG co-immunoprecipitates from the corresponding cell extracts.
APE1-PPI network construction. The gene list of APE1-interacting partners was used to construct the 
corresponding PPI network by defining the interactions between the partners using the InWeb_InBioMap tool, 
applying the suggested parameters110. The APE1-PPI network was represented as an undirected graph (i.e., nodes 
and edges symbolize proteins and interactions between them, respectively), and it was visualized via Cytoscape 
(v3.6.1)38. The network enrichment analysis was performed using the ClueGO tool, using standard parameters111. 
The hubs of the network were obtained by using the Cytohubba tool based on the global metric, betweenness 
centrality112.
Transcription factor binding sites discovery. The FASTA-formatted sequences corresponding to the 
promoters (−2500,−1 nt from the TSS) of the 531 genes of the APE1 interactome were recovered using the 
“getfasta” command of the BEDTools toolset113. Sequences were analyzed using the LASAGNA-Search 2.0 tool to 
identify the presence of enriched transcription factor binding sites (TFBS); the matrix-derived model that used 
JASPAR CORE matrices was selected and the positions of the 145 TF models available were mapped for every 
promoter (Cutoff p-value: 0.001). For each promoter, the top10 results were then identified and used to provide 
the global counts of each TFBS in the analyzed dataset. Finally, the putative binding sites for TFs that underwent 
APE1 redox activity or that played their regulatory activity using APE1 as co-factor were represented as a network 
using Cytoscape, with node size corresponding to the number of identified binding sites.
Tumor datasets and differential gene expression analysis. The differential gene expression results 
from TCGA and normal datasets (GTEX data) for the genes encoding the proteins present in the APE1-PPI 
network were obtained via the GDC data portal hub (https://portal.gdc.cancer.gov/, last accessed July 2018). The 
RUVSeq package inside the R/Bioconductor environment was used to eliminate the batch effect coming from 
the combination of two data sources114. In order to better estimate the differentially expressed genes between the 
tumor and the normal corresponding datasets, we obtained “in-silico empirical” negative controls, i.e., the least 
significantly DE genes based on a first-pass DE analysis performed prior to RUVg normalization114. Empirical 
Distribution analysis, Pearson correlations and Kolmogorov-Smirnov analyses were performed between the gene 
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expression profiles of APE1 and APE1-PPI elements in cancer patients or in the control groups using the stats 
package inside the R/Bioconductor environment. In particular, we compared the correlations of APE1 expression 
vs the PPI network genes expression with respect to: a) APE1 expression vs 100 sets with the same size of the 
PPI genes set composed by random genes; b) 100 random genes expressions vs the PPI network genes; c) APE1 
expression vs all genes.
The analyses of the differentially expressed genes based on GO-CC (Gene Ontology-Cellular Component) was 
performed using the DAVID annotation tool115.
Survival analysis. For each TCGA dataset, differentially expressed genes (multiple correction adjustment 
using the Benjamini-Hochberg method, p < 0.05; absolute log fold change difference ≥1) corresponding to an 
interacting partner of APE1 were used to perform survival analysis. Kaplan-Meier plots were drawn using the 
RTCGA Bioconductor package116, which uses maximally selected rank statistics (maxstat) to determine the opti-
mal cutpoint for continuous variables. Division of the samples was done within the 30–70% percentile range of 
gene expression by the optimal cutpoint value. The Benjamini-Hochberg method was used for p-value correction 
of Kaplan-Meier plots.
Upstream regulators analysis. The set of genes corresponding to APE1 interactors having significant 
differential expression and significant bad survival prognosis was used to define cancer specific bad prognostic 
subnetworks of APE1 for the top 11 TCGA datasets. For each subnetwork, putative master regulators were identi-
fied by the TRANSPATH database (5.1.1.1)117 through the geneXplain platform (geneXplain web edition 4.11)118. 
Identified regulators (max radius: 4; Score cutoff: 0.2; FDR cutoff: 0.05; Z-score cutoff: 1.0) were sorted ascend-
ingly based on the Ranks sum, reflecting a combination of sorting by Score and by Z-score. Upon sorting by Score 
from the biggest values to the lowest, a rank was assigned to the molecules (the molecule with the highest Score 
had rank 1). Upon independent sorting by Z-Score from the biggest values to the lowest, a rank was assigned to 
the molecules (the molecule with the highest Z-score had rank 1). Afterwards, for each molecule, the ranks upon 
sorting by Score and upon sorting by Z-Score were summed up, and the Ranks Sum was generated. The lower the 
Ranks sum, the more interesting the candidate molecule was, with good Score and good Z-score values. The same 
analysis was also repeated on the APE1-PPI network regardless of any differential expression analysis, survival 
probability and cancer type.
Caspases activity assay. Caspase 3/7 activity levels were measured in a fluorescence-based assay using the 
Apo-One® Homogeneous Caspase 3/7 assay (Promega Corp., WI, USA). Assays were performed according to the 
manufacturer’s recommendations. Four-thousands cells were plated onto black 96-well plates and the day after 
cells were treated with Compound #366 in the presence/absence of rotenone (R8875, Sigma-Aldrich) (0.5 μM and 
5 μM), for 24 h. Fluorescence was measured at 521 nm by using a multi-well plate reader (Enspire 2300 Multilabel 
Reader, PerkinElmer). The values were standardized to wells containing media alone.
Data availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the 
PRIDE119 partner repository with the dataset identifier PXD013368. Reviewer account details: Username: 
reviewer03955@ebi.ac.uk Password: Rh2r9CaX.
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